Protective Roles of Apigenin Against Cardiometabolic Diseases: A Systematic Review

Yajie Xu1,2, Xue Li1* and Hui Wang1*

1 State Key Laboratory of Oncogenes and Related Genes, Center for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China, 2 Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai, China

Apigenin is a flavonoid with antioxidant, anti-inflammatory, and anti-apoptotic activity. In this study, the potential effects of apigenin on cardiometabolic diseases were investigated in vivo and in vitro. Potential signaling networks in different cell types induced by apigenin were identified, suggesting that the molecular mechanisms of apigenin in cardiometabolic diseases vary with cell types. Additionally, the mechanisms of apigenin-induced biological response in different cardiometabolic diseases were analyzed, including obesity, diabetes, hypertension and cardiovascular diseases. This review provides novel insights into the potential role of apigenin in cardiometabolic diseases.

Keywords: apigenin, flavonoid, cardiometabolic disease, metabolic syndrome, signaling pathways

INTRODUCTION

Apigenin (4′,5,7-trihydroxyflavone) is named after the genus Apium belonging to family Apiaceae (1). It is widely distributed in vegetables and fruits, such as celery, parsley, oranges and garlic (2), and is also found in herbs such as snow lotus and chamomile (3) (Figure 1A). As a secondary plant metabolite, apigenin is usually stored in plants in a water-soluble glycosylated form (4). Purified apigenin is a yellow powder with a low molecular weight (MW 270.24). It is nearly insoluble in water, moderately soluble in hot alcohol and soluble in dimethyl sulfoxide (DMSO) (5). Pure apigenin is chemically unstable and therefore stored in the dark at −20°C (5).

The biosynthesis of apigenin occurs on the surface of the endoplasmic reticulum and requires four steps including intermediate synthesis, basic skeleton synthesis, precursor synthesis and generation of the apigenin structure (6) (Figure 1B). Current evidence indicates that the bioactivity of apigenin is dependent on its chemical structure, thus the structure-activity relationship of apigenin can be determined by extracting the molecular fragments associated with a specific biological activity. For example, double bonds in the two aromatic rings and hydroxyl groups on C-7 and C-4′ induce the inhibition of α-glucosidase and α-amylase (7). The C- 4′ hydroxyl group in ring B is essential for immunomodulatory properties (8). The hydroxyl radicals at position 5, 7 and 4′ are necessary for Liver X receptor activation (9).

Cardiometabolic disease links the metabolic syndrome disorders (abdominal adiposity, hypertension, dyslipidemia, hyperinsulinemia and glucose intolerance) that are predictive of cardiovascular disease and Type 2 diabetes (T2DM) (10). Recently, apigenin has been found to play...
a protective role in cardiometabolic diseases in vitro and in vivo. This systematic review summarizes the current perspective.

PROTECTIVE ROLES OF APIGENIN IN CARDIOMETABOLIC DISEASES

Protective Role of Apigenin in Obesity and Lipid Metabolism

Obesity is attributed to chronic energy imbalance, including excessive energy intake and limited energy expenditure (11, 12). Anti-obesity strategies focus on suppression of energy intake and stimulation of energy expenditure by regulating lipid metabolism, such as inhibiting pancreatic lipase activity and adipocyte differentiation (13). Studies suggest that apigenin controls energy intake by inhibiting appetite and stimulating energy expenditure by regulating lipid metabolism to alleviate obesity.

First, apigenin inhibits obesity by suppressing food consumption. In vitro and in vivo studies confirmed that apigenin upregulates the expression of anorexigenic neuropeptides pro-opiomelanocortin (POMC) and cocaine- and amphetamine-related transcript (CART), resulting in inhibition of food intake. N-29-2 and SH-SY5Y cells transfected with pPOMC-Luc and pCART-Luc vectors were treated with 0.2–5 µM apigenin for 6 h, resulting in upregulation of pPOMC-Luc and pCART-Luc activity. In an in vitro study, 6-week-old C57BL/6J mice were injected (every 24 h) intraperitoneally with 1 or 10 mg/kg of apigenin in a short-term intervention. Male C57BL/6J mice fed with a high-fat diet (HFD) or a standard laboratory chow diet received 0.05% apigenin for 30 days to demonstrate that apigenin reduces food intake and visceral fat over a long-term period (14). POMC and CART neurons found in the retro-chiasmatic area and throughout the rostrocaudal span of the arcuate nucleus (ARC) play a role in appetite control (15). Increasing expression of POMC and CART induces the expression of leptin receptor B (LeprB) to facilitate leptin binding to LeprB, resulting in an anorectic effect and upregulation of insulin receptors to inhibit appetite.

Secondly, apigenin stimulates energy expenditure by regulating lipid metabolism, including adipogenesis, lipolysis, fatty acid oxidation, and cholesterol synthesis. Recent studies indicate that adipose tissues are generally targeted by apigenin eliciting the following effects:

(1) Stimulation of PPARγ signaling. Several studies have demonstrated that apigenin inhibits adipocyte differentiation via STAT3 (the signal transducer and activator of the transcription 3)-CD36-PPARγ (peroxisome proliferator-activated receptor-gamma) axis (16) and AMPK (5′-adenosine monophosphate-activated protein kinase)/PPARγ axis (17). One study showed that 100 µM apigenin treatment inhibits the differentiation of 3T3-L1 preadipocytes to mature white adipocytes. Mouse models of diet-induced obesity receiving apigenin via subcutaneous injection for 13 days showed that apigenin reduced visceral fat mass (16). Apigenin binds to non-phosphorylated STAT3 to decrease STAT3 phosphorylation and nuclear translocation (18), followed by a decline in the expression of CD36, the downstream target gene involved in fatty acid transport (19). PPARγ is the transcript factor of central ligand-activated transcription factors. It inhibits adipogenesis and controls adipose tissue differentiation to regulate inflammation in obesity. PPARγ expression depends on CD36 expression and therefore apigenin treatment inhibits adipocyte differentiation via downregulation of PPARγ. Other studies reported that apigenin activates the phosphorylation of AMPK (5′-adenosine monophosphate-activated protein kinase) to downregulate adipogenesis via AMPK/PPARγ axis in 3T3-L1 cells treated with 10 µM apigenin for 1 h or 4 days (17) and in HFD mice treated with 200 mg/kg enzyme-treated celery extract (20). AMPK acts as a potential target against adipogenesis (21, 22) and downregulates the expression of PPARγ. The adipogenous genes downstream of PPARγ, such as fatty acid-binding protein 4 and stearoyl-CoA desaturase, are also downregulated, thereby suppressing adipogenesis (17).

(2) Repression of enzyme activity. Guo et al. reported that 0.6 mM apigenin directly inhibits pancreatic lipase activity in vitro (23). Pancreatic lipase catalyzes the conversion of triglycerides to monoglycerides and fatty acids in the intestine. Obesity is alleviated by the suppression of pancreatic lipase, fatty acid synthesis and fat absorption. Gómez-Zorita et al. showed that treatment with 25 µM apigenin decreases the expression of fatty acid synthase (FAS), while increasing the expression of adipose triglyceride lipase (ATGL) in mature adipocytes derived from human mesenchymal stem cells (hMSCs), resulting in reduced adipogenesis (24).

(3) Activation of lipolysis-related genes. Apigenin regulates lipolysis via activation of lipolysis-related genes. In a recent study, 3-week-old HFD mice (C57BL/6J, male) treated with 0.04% apigenin for 12 weeks showed upregulation of lipolysis-related genes in white adipose tissues (WAT), such as FOXO1 (Forkhead Box O1) and SIRT1 (Sirtuin 1) (25).

(4) Induction of fatty acid oxidation. Dietary apigenin induces phosphorylation of AMPK and 1-aminocyclopropane-1-carboxylic acid (ACC) in brown adipose tissues (BAT) to utilize free fatty acids synthesized from white adipose tissues (WAT) (25).

Liver, in addition to adipose tissues, is essential for lipid metabolism. Abnormal lipid metabolism in the liver induced by obesity may cause hepatic steatosis. Apigenin also improves lipid metabolism in the liver to alleviate hepatic steatosis via following mechanisms:

(1) Stimulation of PPARγ signaling. Apigenin modulates PPARγ expression in hepatic lipid metabolism via Nrf2-PPARγ axis. In Hep1-6 cells, apigenin activates nuclear factor erythroid 2-related factor 2 (Nrf2) via translocation into the nucleus to upregulate downstream antioxidant enzymes and downregulate lipid synthesis (26). Activation of Nrf2 by apigenin neutralizes the activation of PPARγ to regulate lipid metabolism in liver (27).

(2) Regulation of SREBP family. Apigenin treatment inhibits lipid homeostasis by the sterol regulatory element-binding protein (SREBP) family. Apigenin significantly decrease lipid accumulation, total intracellular cholesterol (TC), and intracellular triglyceride (TG) levels via the AMPK-SREBP-1/2 (sterol regulatory element-binding protein-1/2) axis in HepG2 cells. Apigenin-induced activation of AMPK downregulates...
the levels of SREBP-1 and SREBP-2 to reduce the synthesis of cholesterol, fatty acids, and triglycerides in the liver. The inhibition of 3-hydroxy-3-methylglutaryl CoA reductase (HMGCR), which is the downstream target gene of SREBP-1 and FAS, the downstream target gene of SREBP-2 also regulates fatty acid and cholesterol synthesis (28).

3. Activation of genes related to fatty acid oxidation and cholesterol homeostasis. Other genes related to fatty acid oxidation and cholesterol homeostasis in the liver, such as short/branched-chain acyl-CoA dehydrogenase (ASADSB), enoyl-CoA-hydratase and 3-hydroxyacyl-CoA dehydrogenase (EHADH), Niemann-Pick type C2 (NPC2) (29), HMG-CoA reductase (HMG-CoAR), low-density lipoprotein receptor (LDL-R), and cytochrome P450 family 7 subfamily A member 1 (CYP7A1) (30) have been reported to decrease with apigenin treatment. In contrast, genes related to lipogenesis, such as PPARγ, lipoprotein lipase (LPL), sterol regulatory element-binding transcription factor 1 (SREBF1), and diacylglycerol O-acyltransferase 2 (DGAT2) were increased in the liver (29).

Obesity-induced oxidative stress and inflammation also aggravate the symptoms of cardiometabolic diseases, leading to multiple cellular disorders (31, 32). Current studies indicate that apigenin alleviates oxidative stress and inflammation by binding to PPARγ as an agonist to regulate M2 polarization with nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) inhibition. Apigenin-induced PPARγ activation blocks p65 nuclear translocation. NF-κB activation is inhibited in adipose tissue macrophages, leading to an increase in M2 macrophage polarization. The anti-inflammatory effects of M2 macrophages alleviate the metabolic disorder caused by obesity-related inflammation. Meanwhile, cytokines such as IL-6, IL-1β, and TNF-α are suppressed by the inhibition of NF-κB signaling (33).
following apigenin treatment. The protective effect of apigenin on adipocyte browning in the inflammatory environment is also mediated via p65/NF-kB pathway. The inflammatory environment suppresses adipocyte browning to reduce lipid metabolism (34). Apigenin suppresses p65 translocation into the nucleus to inhibit NF-kB activation and inflammatory markers in adipocytes to attenuate inflammation and suppress adipocyte browning (25, 35). Apigenin also plays a protective role in the inhibition of white-to-brown adipose tissue differentiation. The inflammation induced via activation of uncoupling protein 1 and PGE2 receptor 4 (EP4) activates the cyclooxygenase 2 (COX2)/prostaglandin E2 (PGE2) axis, resulting in conversion of white to brown adipose tissue to generate heat by excessive energy expenditure (36).

Studies reported that obesity leads to many health complications. First, obesity has been associated with gastrointestinal disorders, such as gastroesophageal reflux disease, irritable bowel syndrome, and dyspepsia (37, 38). Colon inflammation adversely affects enteric motor function, leading to gastrointestinal disorders (39). Apigenin reduces the levels of malondialdehyde (MDA), interleukin-6 (IL-6), and interleukin-1β (IL-1β), as well as eosinophil infiltration in colon tissue to alleviate inflammation. Further, apigenin regulates inducible nitric oxide synthase (iNOS) expression and substance P (SP) levels in high-fat-diet (HFD)-fed obese mice (40). SP is a neurotransmitter that stimulates the contraction of various intestinal tissues and is a neurokinin receptor 1 (41). Obesity induces the expression of SP leading to enhanced tachykinergic transmission in the enteric nervous system, resulting in abnormal colonic motor function. The suppression of SP by apigenin attenuates enteric motor dysfunctions (40). NO produced by iNOS may trigger inflammation and play a role in enteric nitricergic pathways (42). The downregulation of iNOS by apigenin attenuates inflammation and enteric motor dysfunction. The regulation of gut bacteria by apigenin also prevents colonic dysfunction in mice via modulation of NOD-like receptor family pyrin domain containing 6 (Nlrp6) (43). Nlrp6 is highly expressed in the intestine. Nlrp6 deficiency may lead to proliferation of Prevotellaceae, the gut bacteria found in patients with bowel diseases (44), by promoting Nlrp6 inflammasome, IL-18 secretion, and regulation of gut bacterial homeostasis. Further, apigenin improves intestinal dysbiosis via augmentation of Akkermansia and Incertae Sedis along with reduction of Faecalibaculum and Dubosiella at the genus level (45). Obesity has also been associated with sarcopenia (46). Obesity-induced muscle atrophy also contributes to impaired glucose and lipid homeostasis, proinflammatory responses, and insulin resistance (47). Apigenin ameliorates skeletal muscle atrophy by enhancing mitochondrial function in an obese mouse model exposed to HFD and in C2C12 cells. Apigenin treatment upregulated mitochondria-related genes, including peroxisome proliferator-activated receptor-γ coactivator-1α (PGC1α), mt-TFAM (transcription factor of PGC1α), cytochrome C, and somatic cytochrome C (CyCs) following the activation of AMPK. Such upregulation is essential for initiation of mitochondrial biogenesis and improved mitochondrial function alleviating obesity-induced skeletal muscle atrophy (48, 49).

In summary, apigenin alleviates obesity and its complications via a variety of mechanisms including inhibition of appetite, glucose signaling pathways and lipid metabolism. It also regulates the intestinal microbiome, enhances mitochondrial function and diminishes inflammation and oxidative stress. The aforementioned experimental approaches and mechanisms underlying the effects of apigenin on obesity are listed in Table 1. Dosages and duration of apigenin treatment in vivo and in vitro are also listed in Table 1.

Protective Role of Apigenin in Diabetes

Diabetes also plays an important role in cardiometabolic disease (50–52). Several studies investigating the effects of apigenin on type 2 diabetes mellitus (T2DM) report decreased insulin resistance, reduced abnormal glycolipid metabolism, and alleviation of oxidative stress (53, 54).

Insulin resistance plays a significant role in the pathophysiology of T2DM (55). Insulin resistance adversely affects glycometabolism in insulin-targeted organs and tissues (54). Abnormal glycolipid metabolism is a typical clinical manifestation in patients with T2DM (56). Apigenin alleviates insulin resistance and glycolipid metabolic disorders via following mechanisms:

1. Inhibition of insulin receptor kinase. Apigenin inhibits tyrosine nitration of the insulin receptor kinase domain leading to alleviation of insulin resistance. Tyrosine nitration of IRβ (intracellular β subunits of the insulin receptor) may lead to decreased tyrosine phosphorylation, resulting in impaired insulin signal transduction in HFD mice (57). In vitro studies showed that apigenin decreases the Cu²⁺-catalyzed insulin receptor kinase domain fragment KK-1 and inhibits the formation of 3,3′-dityrosine (58).

2. Regulation of miRNAs. Apigenin regulates miRNAs, which are associated with insulin resistance and glucose homeostasis. In vitro experiments involving HuH7 cells and in vivo studies investigating miR103 transgenic mice validates apigenin-mediated inhibition of the phosphorylation of transactivating response RNA-binding proteins (TRBP). Additionally, miRNA-generating complexes inhibited, leading to suppression of precursor miRNA103 maturation expressed in liver and fat, resulting in insulin resistance and impaired glucose metabolism and homeostasis (59, 60). Thus, apigenin-induced suppression of miRNA103 alleviates glucose intolerance (60).

3. Upregulation of GLUT4/AMPK signaling. Apigenin extracted from Sophora davidii (Franch.) promotes glucose transporter 4 (GLUT4) expression and activates AMPK phosphorylation in L6 cells and insulin target tissues in KK-Ay mice (61). In insulin target tissues such as liver and fat, the upregulation of GLUT4 and the activation of AMPK facilitates glucose utilization to ameliorate insulin resistance (62, 63).

4. Inhibition of α-amylase. Several studies reported that apigenin decreases the inhibition of α-amylase in Kunming mice, thus reducing the digestion of dietary carbohydrates (64). The digestive enzyme α-amylase hydrolyzes dietary carbohydrates into disaccharides and polysaccharides (65). Inhibition of the digestion of dietary carbohydrates delays glucose absorption and blocks the progression of T2DM. Therefore, the inhibition of α-amylase by apigenin ameliorates T2DM (64).
TABLE 1 | Experiment designs and effects of apigenin on obesity and lipid metabolism (in vivo and in vitro).

| Study design | Experiment models | Dose | Duration | Administration route | Source | Mechanisms | Reference |
|--------------|-------------------|------|----------|----------------------|--------|------------|-----------|
| In vivo experiment | C57BL/6J mice (high fat diet) | 10 mg/kg | 48 h | Intraperitoneal injection (after modeling) | Seeds of Perilla frutescens Britton var crispa (Benth.) | Increase of POMC and CART expression to inhibit food intake | Myoung et al. (14) |
| | C57BL/6J mice (high fat diet) | 10, 30, and 50 mg/kg | 21 days | Intraperitoneal injection (after modeling) | Commercial | PPARγ activation to suppress NF-κB expression, leading to M2 polarization | Feng et al. (33) |
| | C57BL/6J ob/ob mice | 30 mg/kg | 16 weeks | Food intake (during modeling) | Commercial | Increase of expressions of fatty acid oxidation related genes, decrease of expressions of lipogenic genes | Jung et al. (29) |
| | C57BL/6J mice (high fat diet) | 30 mg/kg | 3 weeks | Intraperitoneal injection (after modeling) | Commercial | Inhibition of PPARγ expression and activation of Nrf2 | Feng et al. (27) |
| | ICR mice (high fat diet) | Not mentioned | 28 days | Intragastric injection (during modeling) | Commercial | Decrease of blood fat, reduced animal weight, and reduced total cholesterol, triglyceride and low-density lipoprotein cholesterol | Zhang et al. (30) |
| | C57BL/6J mice (high fat diet) | 10 mg/kg | 8 weeks | Oral gavage (during modeling) | Commercial | Decrease of MDA, IL-6, IL-1β, SP, and iNOS expression | Gentile et al. (40) |
| | C57BL/6J mice (high fat diet) | 0.04%-supplemented (w/w) | 12 weeks | Food intake (during modeling) | Commercial | Activation of lipolysis and reduction of obesity-induced inflammation | Sun and Qu (25) |
| | C57BL/6J mice (high fat diet) | 15 and 30 mg/kg | 13 days | Subcutaneous injection (after modeling) | Commercial | Decrease of STAT3, CD36 and PPARγ expression | Su et al. (16) |
| | C57BL/6J mice (high fat diet) | Not mentioned | 28 days | Intragastric injection (during modeling) | Commercial | Increase of POMC and CART expression | Myoung et al. (14) |
| In vivo experiment | N29-2 neuronal cells | 0.2, 1, and 5 µM | 6 h | — | Seeds of Perilla frutescens Britton var crispa (Benth.) | Increase of POMC and CART expression | Myoung et al. (14) |
| | Human SHSY5Y cells | 3T3-L1 cells | 1, 10, and 50 µM | 2 days | — | Commercial | AMPK activation to inhibit PPARγ expression | Ono and Fujimori (17) |
| | | 3T3-L1 cells | 40 µM | 4 days | — | Commercial | Decrease of pancreas lipase activity and preadipocyte differentiation | Guo et al. (23) |
| | | ANA cells, RAW264.7 cells | 7.5 µM | 24 h | — | Commercial | M1/M2 polarization | Feng et al. (33) |
| | | Human mesenchymal stem cells (hMSCs) | 1, 10, and 25 µM | 2 days | — | Commercial | Increase of atgl expression and decrease of fas expression | Gómez-Zorita et al. (24) |
| | | THP-1 cells | Not mentioned | 48 h | — | Commercial | Promotion of the efflux rate of [3H] cholesterol, increase of the activity of SOD and the amount of NO | Zhang et al. (30) |
| | | HUVEC, VSC | — | — | — | Commercial | — | — | — |
| | | Hep1-6 cells | 0.2–64 µM | 24 h | — | Commercial | Inhibition of PPARγ expression and activation of Nrf2 | Feng et al. (27) |
| | | HepG2 cells | 0–1280 µM | 24 h | — | Commercial | Activation of lipolysis and reduction of obesity-induced inflammation | Sun and Qu (25) |
| | | Human adipose-derived stem cells (hASCs) | 10 µM | 48 h | — | Commercial | Activation of COX2/PGE2 axis to inhibit inflammation induced adipocyte browning | Okla et al. (35) |
| | | 3T3-L1 cells | 50 and 100 µM | 10 days | — | Commercial | Decrease of PPARγ | Su et al. (16) |

POMC, pro-opiomelanocortin; CART, cocaine- and amphetamine-related transcript; Nrf2, nuclear factor erythroid 2–related factor 2; MDA, malondialdehyde; SP, substance P; iNOS, inducible nitric oxide synthase; STAT3, signal transducer and activator of the transcription 3; CD36, cluster of differentiation 36; AMPK, 5′-adenosine monophosphate-activated protein kinase; COX2, cyclooxygenase 2; PGE2, prostaglandin E2; atgl, adipose triglyceride lipase; fas, fatty acid synthase.
Oxidative stress also triggers β-cell dysfunction, impaired glucose tolerance, and insulin resistance (66). The production of reactive oxygen species (ROS) in oxidative stress exacerbates the progression of T2DM and related complications. Apigenin treatment mitigates oxidative stress and intracellular ROS production via following mechanisms:

1) Decreased ROS production. Apigenin pre-treatment of streptozocin (STZ)-treated RINm5F pancreatic β cells ameliorates STZ-induced intracellular ROS production, as well as DNA damage, lipid peroxidation, and apoptosis. Apigenin pre-treatment upregulates the expression of antioxidant enzymes, such as superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px) in RINm5F pancreatic β cells and diabetic rats (67). SOD catalyzes the conversion of superoxide radicals (O$_{2^-}$) to molecular oxygen (O$_2$) and hydrogen peroxide (H$_2$O$_2$), resulting in a protective effect against ROS in cells (68). Catalase is a highly specific enzyme that catalyzes the decomposition of hydrogen peroxide into water and molecular oxygen (69). GSH-Px is a cytosolic enzyme that catalyzes the reduction of hydrogen peroxide and lipid peroxides by glutathione, releasing water, oxygen, and alcohol (70). These three enzymes are indispensable in defending against free radicals (71).

2) Inhibition of AGE. Apigenin inhibits the formation of advanced glycation end products (AGEs) and thereby alleviates oxidative stress (72). AGE-mediated damage leads to altered protein structure and functions via cross-linking between molecules via the receptor for AGEs (RAGE). AGEs increase ROS formation and damage anti-oxidant systems (73). Apigenin treatment of human blood plasma proteins in vitro reduced the levels of AGEs (72).

3) Regulation of Keap1-Nrf2 signaling. The anti-oxidant function of apigenin is mediated via the Kelch-like ECH-associated protein 1 (Keap1)-Nrf2 axis targeting liver tissues to alleviate oxidative stress (74). Nrf2 is a primary transcription factor interacting with the anti-oxidant response element (ARE) to regulate antioxidant protein expression. Keap1 is the specific repressor of Nrf2, which acts as an adaptor protein of the Cullin3-based ubiquitin E3 ligase complex to facilitate the ubiquitination and subsequent proteolysis of Nrf2 (74), acting as a sensor of oxidative stress (75, 76). Apigenin occupies the Nrf2-binding site to prevent the binding between Keap1 and Nrf2 and thereby promotes nuclear translocation of Nrf2, thus facilitating its anti-oxidant function (74).

Eventually, persistent inflammation leads to pathogenesis of diabetes (77). Apigenin significantly prevents mitogen-activated protein kinase activation (MAPK) from inhibiting inflammation (NF-kB-TNF-α axis) and apoptosis (increased expression of Bcl-2 and decreased Bax and caspase-3) in diabetic rats (78).

Currently, the apigenin-mediated regulation of blood glucose homeostasis can be summarized as follows: regulating the key enzymes and improving oxidative stress as well as inflammation. A detailed summary of the studies discussed above and the proposed mechanisms of apigenin-mediated effects in diabetes are presented in Table 2. Dosages and duration of apigenin treatments in vivo and in vitro are also listed in Table 2.

### Protective Role of Apigenin in Hypertension
Hypertension plays a central role in cardiometabolic diseases (79), which is prevalent in almost 80% of patients with metabolic syndrome (80). Recent studies reported that apigenin improves hypertension via attenuation of oxidative stress and recovery of mitochondrial dysfunction.

Apigenin plays a protective role in hypertension by alleviating oxidative stress. Apigenin can significantly restore normal blood pressure and reverse renal damage in cyclosporine-induced hypertensive Sprague-Dawley rats by decreasing lipid hydroperoxides and increasing anti-oxidant levels (81). Apigenin also controls elevated blood pressure in N-nitro-L-arginine methylster-induced hypertensive Sprague-Dawley rats by improving NO bioavailability, attenuating oxidative stress, and reducing vascular damage (82).

Apigenin also regulates pulmonary hypertension (PH). Mitochondrial dysfunction plays a vital role in PH, it may lead to the imbalance of ion homeostasis and downregulation of enzymes in apoptosis (83). Apigenin activates mitochondria-dependent apoptosis via hypoxia-inducible factor 1α (HIF-1α)-KV1.5 channel pathway. The inhibition of HIF-1α by apigenin upregulates the expression of KV1.5 channels to restore mitochondrial function, thereby attenuating PH (84).

Apigenin has also been reported to diminish the complications induced by hypertension, such as renal damage and fibrosis due to abnormal collagen accumulation in kidneys (85). Apigenin significantly attenuates hypertension and renal fibrosis in deoxycorticosterone acetate (DOCA)-salt-induced hypertensive rats (86). Apigenin activates transient receptor potential vanilloid 4 (TRPV4), a non-selective cation channel widely expressed in the kidney. Ca$^{2+}$ influx is then promoted in vascular endothelium and smooth muscle to induce vasodilation (87) and activation of the AMPK/SIRT1 signaling pathway to inhibit the TGF-β1 and Smad-2/3 signaling pathway (Smad and Mad proteins from Caenorhabditis elegans and Drosophila, respectively). This inhibition stimulates cellular transformation into fibroblasts and increases the synthesis of matrix proteins to induce renal fibrosis (86, 88, 89). Thus, apigenin alleviates renal fibrosis and structural and functional damage.

Current evidence suggests that apigenin decreases blood pressure mainly via improved NO bioactivity and oxidative stress, regulation of apoptosis-related mitochondrial genes and promotion of vasodilation in vascular endothelium. Experimental studies and mechanisms of action involving apigenin in hypertension are listed in Table 3. Experimental dosages and durations of apigenin treatment in vivo and in vitro are listed in Table 3.

### Protective Role of Apigenin in Cardiovascular Diseases
Apigenin prevents cardiovascular diseases via antioxidant and anti-apoptotic mechanisms in vascular endothelial cells and cardiomyocytes.

Vascular endothelial dysfunction is a major mediator in cardiovascular diseases (90). Abnormal glucose metabolism
| Study design | Experiment models | Dose | Duration | Administration route | Source | Mechanisms | Reference |
|--------------|-------------------|------|----------|----------------------|--------|------------|-----------|
| **In vivo experiment** | miRNA103 transgenic mice | 40 mg/kg | 14 days | Intraperitoneal injection (after modeling) | Commercial | Inhibition of miRNA103 maturation | Ohno et al. (60) |
| | Wistar rats | 10, 20, and 40 mg/kg | 21 days | Intraperitoneal injection (after modeling) | Commercial | decrease of MDA content, increase of SOD activity and GSH level | Mao et al. (67) |
| | Sprague-Dawley rats | 50 and 100 mg/kg | 6 weeks | Oral gavage (after modeling) | Commercial | Inhibition of NF-κB activation and ICAM-1 mRNA expression | Ren et al. (97) |
| | CS7BL/6J mice (high fat diet) | 0.005% (w/w) | 16 weeks | Food intake (during modeling) | Commercial | Upregulated expression of genes regulating fatty acid oxidation, TCA cycle and cholesterol homeostasis, downregulated expression of lipogenic genes in the liver | Jung et al. (29) |
| **In vitro experiment** | CS7BL/6J mice (high fructose diet) | 50 mg/kg | 4 weeks | Oral gavage (during modeling) | Commercial | Inhibition of binding of Keap1 to Nrf2 to increase the expressions of anti-oxidative genes | Yang et al. (126) |
| | Huh7 cells | 10 µM | 24 h | — | Commercial | Inhibition of miRNA103 maturation | Ohno et al. (60) |
| | Hep3B cells, U-2 OS cells | 30 µM | 16 h | — | Commercial | Rapid intracellular translocation of FOXO1, downregulation of PEPCk, G6Pc, FASN and ACC, inhibition of the PkB/AKT-signaling pathway | Bumke-Vogt et al. (134) |
| | HepG2 cells | 20 µM | — | — | Commercial | Reduction of intracellular ROS production, alleviation of DNA damage, lipid peroxidation, cell apoptosis of pancreatic beta cells, the loss of antioxidant enzymes | Wang et al. (71) |
| | HEK cells | 20 µM | — | — | Commercial | — | — | — |
| | RINm5F rat pancreatic β cells | 5 µM | 1 h | — | Commercial | — | — | — |
| | Inhibition of apigenin against pancreatic α-Amylase | 400 µM | 10 min | — | Commercial | Inhibition against α-Amylase | Zhang et al. (64) |
| | H9c2 cells | 1, 3, and 10 µM | 20 h | — | Commercial | Inhibition of HIF-1α to improve abnormal glucolipid metabolism | Zhu et al. (105) |
| | Detection of Tyr phosphorylation: KK-1 | 40 µM | 6 h | — | Commercial | Inhibition of tyrosine nitration of the insulin receptor kinase domain to alleviate insulin resistance | Fang et al. (58) |

Keap1, Kelch-like ECH-associated protein 1; Nrf2, nuclear factor erythroid 2-related factor 2; 2-NBDG, 2-[N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxy-D-glucose; ROS, reactive oxygen species; PKCβII, protein kinase C βII; HIF-1α, hypoxia-inducible factor 1 alpha.
### TABLE 3 | Experiment designs and effects of apigenin on hypertension (in vivo and in vitro).

| Experiment models | Dose | Duration | Administration route | Sources | Mechanisms |
|-------------------|------|----------|----------------------|---------|------------|
| **In vivo**       |      |          |                      |         |            |
| Sprague-Dawley rats | 1, 10, 15, and 20 mg/kg | 2 weeks | Commercial | Wei et al. (80) | Reduction of lipid peroxides and increase of total antioxidant levels |
| Sprague-Dawley rats | 1 mg/kg | 6 weeks | Drinking water (during administration) | Wei et al. (80) | Improvement of NO bioavailability and endothelial and vascular function, alleviation of oxidative stress |
| **In vitro**       |      |          |                      |         |            |
| HBZY-1 cells, M1CCD | 0.2% supplement | 24 h | Commercial | Wei et al. (83) | TRPV4-mediated activation of AMPK/SIRT1 and inhibition of TGF-β1/Smad2/3 signaling pathway |

**Sources:** Commercial.

**Mechanisms:**
- Reduction of lipid peroxides and increase of total antioxidant levels.
- Improvement of NO bioavailability and endothelial and vascular function, alleviation of oxidative stress.
- TRPV4-mediated activation of AMPK/SIRT1 and inhibition of TGF-β1/Smad2/3 signaling pathway.

**References:**
- Haleagrahara et al. (81)
- Paredes et al. (82)
- He et al. (84)
- Wei et al. (86)

---

and oxidative stress in vascular endothelial cells may lead to vascular endothelial dysfunction. Several studies have discussed the ameliorative effect of apigenin on endothelial dysfunction. First, apigenin increases apelin expression to rescue endothelial dysfunction. Apelin is an endogenous ligand for the G-protein-coupled APJ receptor expressed in the cardiovascular system. It increases glucose uptake and SOD activity, reversing the impaired glucose metabolism and homeostasis and the severe oxidative stress in human endothelial cells (91-94). Oxidative stress in endothelial cells leads to endothelial dysfunction and angiogenesis (92). The suppression of apelin in human endothelial cells can be reversed by apigenin treatment. Second, apigenin inhibits NF-κB-associated signaling pathways and suppresses intercellular adhesion molecule-1 (ICAM-1) expression in vascular endothelial dysfunction. ICAM-1 is a cell surface receptor that binds lymphocyte function-associated antigen 1 (LFA-1), mediating the interaction between keratinocytes and leukocytes (95). ICAM-1 plays an essential role in controlling abnormal inflammatory infiltration, adhesion, and migration (96). Apigenin inhibits NF-κB activation to improve NO production and SOD activity in endothelial cells and suppress ICAM-1 expression in human vascular endothelial cells (HUVECs) (97). Third, apigenin inactivates the PI3K (phosphoinositide-3-kinase) Akt (protein kinase B) axis in HUVECs during vascular endothelial dysfunction. The PI3K/Akt axis is an essential pathway in the pathogenesis of cardiovascular complications in T2DM (98). Apigenin treatment inhibited the phosphorylation of Akt-residues Ser473 and Thr308 to prevent vascular endothelial dysfunction (99). Finally, apigenin decreased ROS and improved NO levels to alleviate vascular endothelial dysfunction induced by mitochondrial-dependent apoptosis via inhibition of protein kinase C βII (PKCβII) phosphorylation. PKCβII promotes oxidative stress, ROS production and mitochondria-dependent apoptosis in vascular endothelial dysfunction (100, 101). Apigenin treatment upregulated the expression of the anti-apoptotic gene, B-cell lymphoma-2 (Bcl-2), while the pro-apoptotic gene, Bcl-2 associated X (Bax), was downregulated, resulting in attenuation of mitochondria-dependent apoptosis in endothelial cells (102).

Further, cardiac hypertrophy is another manifestation of cardiovascular diseases (103). Current evidence suggests that abnormal glycolipid metabolism and overexpression of HIF-1α in cardiac cells causes cardiac hypertrophy (104). In **in vivo** and **in vitro** experimental data suggest that apigenin alleviates cardiac hypertrophy via suppression of HIF-1α, thereby reversing the expression of PPARα/γ and target genes including glycerol-3-phosphate acyltransferase (GPAT), glucose transporter 4 (GLUT-4), carnitine palmitoyltransferase 1 (CPT-1) and pyruvate dehydrogenase kinase 4 (PDK-4). Downregulation of GLUT4 and upregulation of PDK-4 can inhibit excessive glucose intake and oxidation, preventing abnormal glucose metabolism. Downregulation of GPAT and upregulation of CPT-1 decreases the rate of triglyceride synthesis and augments fatty acid oxidation, thereby improving lipid metabolism (105, 106). Thus, the hypoxic myocardial energy utilization (107-110) can be reversed.
In summary, apigenin can ameliorate cardiovascular diseases via reduction of oxidative stress and mitochondria-dependent apoptosis in vascular endothelial cells as well as regulation of glucose and lipid metabolism in cardiomyocytes. The experimental studies and mechanisms of action involving apigenin in hypertension are presented in Table 4. Experimental dosages and duration of apigenin treatment in vivo and in vitro are also listed in Table 4.

Apigenin Analogs and Their Effects on Alleviating Cardiometabolic Diseases

Apigenin analogs are derived from the basic flavonoid skeleton via hydroxyl group substitution, glycosylation, hydroxylation, and methylation (111, 112). In plants, apigenin is stored as glycosides such as apigenin 7-O-apioglucoside in celery and parsley (113, 114) and apigenin 8-C-glucoside isolated from bamboo leaves (115). Several apigenin analogs carry the basic flavonoid skeleton similar to apigenin and exhibit biological activity in cardiometabolic diseases.

(1) Apiin. Apiin (apigenin 7-O-apioglucoside) is derived from celery and exhibits anti-adipogenic and anti-obesity effects in HFD mice via the AMPK/PPARγ axis (20), similar to apigenin. Apiin also alleviates insulin resistance in HFD mice via downregulation of glucogenic genes, PEPCK (phosphoenolpyruvate carboxykinase) and G6Pase (glucose-6-phosphatase) in the liver, and promotion of glycogen synthesis via inhibition of glycogen synthase phosphorylation and induction of GSK3β (glycogen synthase kinase3β) phosphorylation (116).

(2) Apigetrin. Apigetrin (apigenin 7-glucoside) ameliorated pancreatic β cell damage via reduction of endoplasmic reticulum (ER) stress in RINm5F cells via the regulation of ER stress biomarkers, such as upregulation of CCAAT/enhancer-binding protein homologous protein (C/EBP), induction of spliced X-box binding protein 1 (XBP1), phosphorylation of protein kinase RNA-like ER kinase (PERK) and eukaryotic initiation factor 2α (eIF2alpha), and cleavage of caspase-12 (117).

(3) Vitexin. Vitexin (apigenin 8-C-glucoside) regulates lipid metabolism via AMPK-mediated pathway in 3T3-L1 cells (118) in vitro and the liver of HFD mice (119) in vivo to alleviate obesity and non-alcoholic fatty liver disease. Vitexin also protects pancreatic β-cells via inhibition of high mobility group box 1 (HMGB1) (120), which is released from damaged pancreatic β-cells and induces inflammation in LPS (lipopolysaccharide)-induced rats and LPS-treated INS-cells.

(4) Acacetin. Acacetin (4′-methoxy 5,7-dihydroxylavone) suppress adipogenesis in 3T3-L1 cells and HFD mice via upregulation of SIRT1 expression and AMPK phosphorylation (121). Acacetin also increases glucose uptake by enhancing GLUT4 translocation to the plasma membrane via the CaMKII-AMPK pathway by increasing intracellular calcium concentrations in L6 and HepG2 cells (122). In addition to regulating glycometabolism, acacetin alleviates endothelial dysfunction in insulin-resistant rats by inhibiting the release of inflammatory factors, such as NF-κB and IL-1β, and improving vasodilatory function via the estrogen signaling pathway (123).
FIGURE 2 | Potential signaling pathways of apigenin affecting cardiometabolic diseases in different types of cells. (A) Potential signaling pathways of apigenin affecting cardiometabolic diseases in adipose tissue macrophages. p65: RelA, NF-κB component. P50: p50 NF-κB component. (B) Potential signaling pathways of apigenin affecting cardiometabolic diseases in adipocytes. AMPK, AMP-activated protein kinase. p65: RelA, NF-κB component. STAT3, Signal transducer and activator of transcription 3. (C) Potential signaling pathways of apigenin affecting cardiometabolic diseases in hepatocytes. AMPK, AMP-activated protein kinase. (Continued)
(5) **Apigenin 7, 4′-dimethyl ether.** Apigenin 7, 4′-dimethyl ether (ADE) enhances glucose uptake in L6 cells and inhibits α-glucosidase enzyme (124), which releases glucose to form glycolipid and glycopeptide via hydrolyzation of α-glycosidic bonds from the non-reducing ends of oligosaccharide substrates and transfer of free glucose residues to another carbohydrate substrate.

(6) **8-(6″-umbelliferyl)-apigenin.** 8-(6″-umbelliferyl)-apigenin promotes glucose uptake in 3T3-L1 cells, indicating improved glucose consumption (125).

**POTENTIAL SIGNALING PATHWAYS MEDIATED BY APIGENIN FOR AMELIORATION OF CARDIOMETABOLIC DISEASE IN DIFFERENT CELL TYPES**

In summary, the potential signaling pathways mediated by apigenin resulting in alleviation of cardiometabolic diseases in different cell types are illustrated in **Figures 2A–E.** Apigenin alleviates cardiometabolic diseases mainly by regulating glycolipid metabolism, oxidative stress, and oxidative stress-induced inflammation and apoptosis. Notably, apigenin plays contrasting roles in different types of cells. Apigenin acts as an agonist of PPARγ in adipose tissue macrophages. PPARγ binds to p65 to inhibit nuclear translocation to block NF-κB signaling pathway resulting in attenuation of inflammation (Figure 2A) (33). However, apigenin inhibits PPARγ expression in adipocytes, hepatocytes, and cardiomyocytes by acting as an antagonist (Figures 2B–D).

**Apigenin in Adipocytes**

In adipocytes, apigenin acts as a functional regulator of lipid metabolism to reduce fat accumulation. Apigenin downregulates PPARγ expression by inhibiting the STAT3/CD36 axis (16) and the activation of AMPK (17). Apigenin directly induces p65 phosphorylation to prevent its nuclear translocation to ensure continued inhibition of NF-κB signaling in the absence of PPARγ as a mediator (25, 35).

**Apigenin in Hepatocytes**

Since the liver is an important site of energy metabolism, apigenin is a potential mediator of glycolipid metabolism in hepatocytes. Apigenin acts as a PPARγ antagonist via direct activation of Nrf2 and indirect activation of Nrf2 via the Keap1-Nrf2 pathway (126). Additionally, apigenin activates AMPK to inhibit SREBP-1 and SREBP-2 to regulate hepatic fatty acid oxidation and cholesterol synthesis (28).
Apigenin in Cardiomyocytes
Apigenin treatment of cardiomyocytes regulates glucose and lipid metabolism to maintain normal cellular function. HIF-1α activation via apigenin regulates the PPAR family, leading to the appropriate regulation of downstream target genes related to glycolipid metabolism. Apigenin suppresses PPARγ expression via the activation of HIF-1α as an antagonist (105, 106). Meanwhile, the upregulation of HIF-1α following apigenin treatment increases PPARα expression (105, 106).

Apigenin in Endothelial Cells
Apigenin plays a protective role in vascular endothelial dysfunction by regulating several signaling pathways in endothelial cells to alleviate oxidative stress, inflammation, and mitochondria-dependent apoptosis. The inhibition of the NF-κB signaling pathway with apigenin treatment also ameliorates inflammatory response in endothelial cells and increases NO production (97). NF-κB inhibition also suppresses the expression of ICAM-1 to improve abnormal inflammatory adhesion, migration, and infiltration, resulting in the alleviation of vascular endothelial dysfunction (97). In addition to NF-κB pathways, apigenin also activates the PI3K-Akt pathway and inhibits PKCβII activation by reducing oxidative stress and oxidative stress-related apoptosis in mitochondria (102). The expression of anti-apoptotic gene, Bcl-2, and the pro-apoptotic gene, Bax, in these two pathways reduces abnormal apoptosis. The activation of the PI3K-Akt pathway also promotes eNOS activity to restore NO levels and thereby attenuates oxidative stress (102). Apigenin treatment also mitigates angiogenesis induced by inflammation. HIF-1α inhibition by apigenin directly reduces the expression of vascular endothelial growth factor (VEGF) in angiogenesis, thus alleviating the angiogenesis induced by vascular dysfunction (127).

CONCLUSION AND PERSPECTIVES
A review of studies investigating apigenin suggests critical biological mechanisms, including reducing oxidative stress and oxidative stress-induced inflammation and apoptosis, and improving glycolipid metabolism. Figure 3 summarizes the potential signaling pathways of apigenin underlying the protection against cardiometabolic diseases.

The molecular structure of apigenin suggests poor water solubility, chemical instability and moderate permeability, which prevent maximum bioavailability. Therefore, new delivery and design strategies have been formulated including the development of apigenin glycosides and acylated derivatives to enhance water solubility (128, 129). Apigenin-AuNP complex can be developed at room temperature at pH 10 to enhance the stability of apigenin in the body (130). Nano-apigenin using poly (lactic-co-glycolide) (PLGA) can also improve the bioactivity of apigenin (131). Pharmacokinetic and pharmacodynamic profiles of apigenin in rats and mice have been studied. The peak plasma concentration Cmax and the time to reach the peak plasma concentration Tmax were 1.07 ng/mL and 1 h, respectively, and the area under the concentration-time curve (AUC 0−24) was 3.9 ng h/mL in mice (132). However, the bioavailability of apigenin in humans is still unknown. Further studies are needed to confirm the bioavailability and safety profile in humans.

In summary, the extensive review and validation of in vitro and in vivo evidence suggests that apigenin is a natural compound that can be used to protect against cardiometabolic diseases. Environment-wide association studies (EWAS) also indicate that apigenin is one of the protective factors in cardiovascular diseases at the population level (133). Further studies are required to establish the optimum dose of apigenin in alleviating cardiometabolic diseases in humans, developing a novel approach for clinical management of the disease.

AUTHOR CONTRIBUTIONS
XL designed this review, helped with writing and revising of the manuscript, and provided critical feedback. YX contributed to collecting and screening the literature, as well as summarizing the data, and then composed and revised the manuscript. HW reviewed the manuscript. All authors were involved in final approval of the submitted version.

FUNDING
This study was supported by grants from the National Nature Science Foundation (81830215 and 81630086); three-year Action Program of Shanghai Municipality for Strengthening the Construction of Public Health System (GWV-10.2-QY34); the National Key R&D Program of China (2018YFC2000700); the Key Research Program (ZDRW-ZS-2017-1) of the Chinese Academy of Sciences; innovative research team of high-level local Universities in Shanghai; Medicine and Engineering Interdisciplinary Research Fund of Shanghai Jiao Tong University (YG2020YQ06).

REFERENCES
1. Sung B, Chung HY, Kim ND. Role of apigenin in cancer prevention via the induction of apoptosis and autophagy. J Cancer Prev. (2016) 21:216–26. doi: 10.15430/JCP.2016.21.4.216
2. Madunić J, Madunić IV, Gaiksi G, Popić J, Garaj-Vrhovac V. Apigenin: a dietary flavonoid with diverse anticancer properties. Cancer Lett. (2018) 413:11–22. doi: 10.1016/j.canlet.2017.10.041
3. Huang WY, Cai YZ, Zhang Y. Natural phenolic compounds from medicinal herbs and dietary plants: potential use for cancer prevention. Nutr Cancer. (2010) 62:1–20. doi: 10.1080/01635580903191585
4. Svehlikova V, Bennett RN, Mellon FA, Needs PW, Piacente S, Kroon PA, et al. Isolation, identification and stability of acylated derivatives of apigenin 7-O-glucoside from chamomile (Chamomilla recutita L. Rauschert). Phytochemistry. (2004) 65:2323–32. doi: 10.1016/j.phytochem.2004.07.011
5. Saldanha E, Pai RJ, George T, D’Souza S, Adnan M, Pais M, et al. Health effects of various dietary agents and phytochemicals (Therapy of acute pancreatitis). In: Grumescu AM, Holban AM editors. Therapeutic, Probiotic, and
25. Sun Y-S, Qu W. Dietary apigenin promotes lipid catabolism, thermogenesis, and browning in adipose tissues of HFD-Fed mice. *Food Chem Toxicol.* (2019) 133:117080. doi: 10.1016/j.fct.2019.110780

26. Bollong MJ, Lee G, Coukos JS, Yun H, Zambaldo C, Chang JW, et al. Metabolite-derived protein modification integrates glycolysis with KEAP1-NRF2 signalling. *Nature.* (2018) 562:600–4. doi: 10.1038/s41586-018-0622-0

27. Feng X, Yu W, Li X, Zhou E, Zhang W, Shen Q, et al. Apigenin, a modulator of PPARy, attenuates HFD-induced NAFLD by regulating hepatic lipid metabolism and oxidative stress via Nrf2 activation. *Biochem Pharmacol.* (2017) 136:136–49. doi: 10.1016/j.bjcp.2017.04.014

28. Lu J, Meng Z, Cheng B, Liu M, Tao S, Guan S. Apigenin reduces the excessive accumulation of lipids induced by palmitic acid via the AMPK signaling pathway in HepG2 cells. *Exp Ther Med.* (2019) 18:2965–71. doi: 10.3892/etm.2019.7905

29. Jung UJ, Cho Y-Y, Choi M-S. Apigenin ameliorates dyslipidemia, hepatic steatosis and insulin resistance by modulating metabolic and transcriptional profiles in the liver of high-fat diet-induced obese mice. *Nutrients.* (2016) 8:305. doi: 10.3390/nu8050305

30. Zhang K, Song W, Li D, Jin X. Apigenin in the regulation of cholesterol metabolism and protection of blood vessels. *Exp Ther Med.* (2017) 13:1719–24. doi: 10.3892/etm.2017.4165

31. Leisegang K, Henkel R, Agarwal A. Obesity and metabolic syndrome associated with systemic inflammation and the impact on the male reproductive system. *Am J Reprod Immunol.* (2019) 82:e13178. doi: 10.1111/aji.13178

32. Lauridsen C. From oxidative stress to inflammation: redox balance and immune system. *Front. Immunol.* (2017) 15:237. doi: 10.3389/fimmu.2016.00177

33. Feng X, Weng D, Zhou F, Owen YD, Qin H, Zhao J, et al. Activation of PPARgamma by a natural flavonoid modulator, apigenin ameliorates obesity-related inflammation via regulation of macrophage polarization. *EBioMedicine.* (2016) 9:61–76. doi: 10.1016/j.ebiom.2016.06.017

34. Villarroya F, Cereijo R, Gavaldá-Navarro A, Villarroya J, Giralt M. Inflammation of brown/beige adipose tissues in obesity and metabolic disease. *J Intern Med.* (2018) 284:492–504. doi: 10.1111/joim.12803

35. Okla M, Al Madani JO, Chung S, Alafyey M. Apigenin reverses interleukin-1β-induced suppression of adipocyte browning via COX2/PGE2 signaling pathway in human adipocytes. *Mol Nutr Food Res.* (2020) 64:e1900925. doi: 10.1002/mnfr.201900925

36. Garcia-Alonso V, Claria J. Prostaglandin E2 signals white-to-brown adipigenic differentiation. *Adipocyte.* (2014) 3:290–6. doi: 10.4161/adip.29993

37. Fujimoto A, Hoteya S, Iizuka T, Ogawa O, Mitani T, Kuroki Y, et al. Obesity and gastrointestinal diseases. *Gastroenterol Hepatol.* (2013) 37:6571–9. doi: 10.1007/s00462-016-0828-5

38. Lauridsen C. From oxidative stress to inflammation: redox balance and immune system. *Front. Immunol.* (2017) 15:237. doi: 10.3389/fimmu.2016.00177

39. Lauridsen C. From oxidative stress to inflammation: redox balance and immune system. *Front. Immunol.* (2017) 15:237. doi: 10.3389/fimmu.2016.00177

40. Gentile D, Fornai M, Colucci R, Pellegrini C, Tirotta E, Benvenuti L, et al. Activation of PPARγ by a natural flavonoid modulator, apigenin ameliorates obesity-related inflammation via regulation of macrophage polarization. *EBioMedicine.* (2016) 9:61–76. doi: 10.1016/j.ebiom.2016.06.017

41. Villarroya F, Cereijo R, Gavaldá-Navarro A, Villarroya J, Giralt M. Inflammation of brown/beige adipose tissues in obesity and metabolic disease. *J Intern Med.* (2018) 284:492–504. doi: 10.1111/joim.12803

42. Okla M, Al Madani JO, Chung S, Alafyey M. Apigenin reverses interleukin-1β-induced suppression of adipocyte browning via COX2/PGE2 signaling pathway in human adipocytes. *Mol Nutr Food Res.* (2020) 64:e1900925. doi: 10.1002/mnfr.201900925

43. Garcia-Alonso V, Claria J. Prostaglandin E2 signals white-to-brown adipigenic differentiation. *Adipocyte.* (2014) 3:290–6. doi: 10.4161/adip.29993

44. Elinav E, Strowig T, Kau AL, Henao-Mejia J, Thaiss CA, Booth CJ, et al. Metabolite-derived protein modification integrates glycolysis with KEAP1-NRF2 signalling. *Nature.* (2018) 562:600–4. doi: 10.1038/s41586-018-0622-0

45. Qiao Y, Zhang Z, Zhai Y, Yan X, Zhou W, Liu H, et al. Apigenin alleviates high-fat-induced hepatic steatosis and insulin resistance by modulating metabolic and transcriptional profiles in the liver of high-fat diet-induced obese mice. *Nutrients.* (2016) 8:305. doi: 10.3390/nu8050305
46. Lipina C, Hundal HS. Lipid modulation of skeletal muscle mass and function. J Cachexia Sarcopenia Muscle. (2017) 8:190–201. doi: 10.1002/jcms.12144

47. Perry BD, Caldow MK, Brennan-Speranza TC, Sharaglia M, Jerums G, Garnham A, et al. AMPK in diabetes: a role in fasting and postprandial glycemia. Front Immunol. (2016) 22:94–109.

48. Choi WH, Son HI, Jang YJ, Ahn J, Jung CH, Ha TY. Apigenin ameliorates the obesity-induced skeletal muscle atrophy by attenuating mitochondrial dysfunction in the muscle of obese mice. Mol Nutr Food Res. (2017) 61:170218. doi: 10.1002/mnfr.201700218

49. Deng X, Zhang S, Wu J, Sun X, Shen Z, Dong J, et al. Promotion of mitochondrial biogenesis via activation of AMPK-PGC1α signaling pathway by ginger (Zingiber officinale Roscoe) extract, and its major active component 6-Gingerol. J Food Sci. (2019) 84:2101–11. doi: 10.11170.3841.14723

50. Hernandez AF, Green JB, JannMohamed S, D’Agostino RB Sr, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. (2018) 392:1519–29. doi: 10.1016/S0140-6736(18)32261-X

51. van Sloten TT, Sedaghat S, Carneeth MR, Launer LJ, Stenhower CDA. Cerebral microvascular complications of type 2 diabetes: stroke, cognitive dysfunction, and depression. Lancet Diabetes Endocrinol. (2020) 8:325–36. doi: 10.1016/S2213-8587(19)30405-X

52. Douros A, Filion KB, Yin H, Yu OH, Elmimam M, Udell JA, et al. Glucagon-like peptide 1 receptor agonists and the risk of incident diabetic retinopathy. Diabetes Care. (2018) 41:2330. doi: 10.2337/dc18-012005

53. Taylor R. Type 2 diabetes: etiology and reversibility. Diabetes Care. (2010) 33:197–205. doi: 10.2337/dc10-0070

54. Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. Pharm Des. (2001) 280:C970–9. doi: 10.1152/ajpcell.2001.280.4.C970

55. Li L, Leung PS. Pancreatic cancer, pancreatitis, and oxidative stress. In: Cadenas E, Packer L editors. Methods in Enzymology. Cambridge, MA: Academic Press. (2019) pp. 173–86. doi: 10.1016/b978-0-12-058377-5.00012-6

56. Covas G, Marinho HS, Cyrne L, Antunes F. Activation of Nrf2 by H2O2: de novo synthesis versus nuclear translocation. In: Cadenas E, Packer L editors. Methods in Enzymology. Cambridge, MA: Academic Press. (2013). pp. 157–71. doi: 10.1016/b978-0-12-405388-1.00009-4

57. Pedersen BK. Anti-inflammatory effects of exercise: role in diabetes and cardiovascular disease. Eur J Clin Invest. (2017) 47:680–11. doi: 10.1111/eci.12781

58. Malik S, Suchal K, Khan SI, Bhatia J, Kishore K, Dinda AK, et al. Apigenin ameliorates streptozotocin-induced diabetic nephropathy in rats via MAPK-NF-κB-TNF-α and TGF-β1-MAPK-fibronectin pathways. Am J Physiol Renal Physiol. (2017) 53:554–63. doi: 10.1152/ajprenal.00393.2016

59. Haleagrahara N, Chakravarthi S, Bangra Kulur A, Yee TM. Plant flavone apigenin protects against cyclosporine-induced histological and biochemical changes in the kidney in rats. Int J Clin Pract. (2006) 60:308–14. doi: 10.1111/j.1751-1437.2006.tb07014.x

60. Katsimardou A, Imprialos K, Stavropoulos K, Sachinidis A, Doumas M, Lascaratos J. Activation of Nrf2 by H2O2: de novo synthesis versus nuclear translocation. In: Cadenas E, Packer L editors. Methods in Enzymology. Cambridge, MA: Academic Press. (2019) pp. 173–86. doi: 10.1016/b978-0-12-805377-5.00012-6

61. Pedersen BK. Anti-inflammatory effects of exercise: role in diabetes and cardiovascular disease. Eur J Clin Invest. (2017) 47:680–11. doi: 10.1111/eci.12781

62. Malik S, Suchal K, Khan SI, Bhatia J, Kishore K, Dinda AK, et al. Apigenin ameliorates streptozotocin-induced diabetic nephropathy in rats via MAPK-NF-κB-TNF-α and TGF-β1-MAPK-fibronectin pathways. Am J Physiol Renal Physiol. (2017) 53:554–63. doi: 10.1152/ajprenal.00393.2016

63. Tajic I, Lovic D. Hypertension and cardiometabolic diseases. Front Biosci (Schol Ed). (2018) 10.16674/si5.0001099

64. Katsimardou A, Imprialos K, Stavropoulos K, Sachinidis A, Doumas M, Lascaratos J. Activation of Nrf2 by H2O2: de novo synthesis versus nuclear translocation. In: Cadenas E, Packer L editors. Methods in Enzymology. Cambridge, MA: Academic Press. (2013). pp. 157–71. doi: 10.1016/b978-0-12-405388-1.00009-4

65. Pedersen BK. Anti-inflammatory effects of exercise: role in diabetes and cardiovascular disease. Eur J Clin Invest. (2017) 47:680–11. doi: 10.1111/eci.12781

66. Malik S, Suchal K, Khan SI, Bhatia J, Kishore K, Dinda AK, et al. Apigenin ameliorates streptozotocin-induced diabetic nephropathy in rats via MAPK-NF-κB-TNF-α and TGF-β1-MAPK-fibronectin pathways. Am J Physiol Renal Physiol. (2017) 53:554–63. doi: 10.1152/ajprenal.00393.2016

67. Tajic I, Lovic D. Hypertension and cardiometabolic diseases. Front Biosci (Schol Ed). (2018) 10.16674/si5.0001099

68. Katsimardou A, Imprialos K, Stavropoulos K, Sachinidis A, Doumas M, Lascaratos J. Activation of Nrf2 by H2O2: de novo synthesis versus nuclear translocation. In: Cadenas E, Packer L editors. Methods in Enzymology. Cambridge, MA: Academic Press. (2013). pp. 157–71. doi: 10.1016/b978-0-12-405388-1.00009-4

69. Pedersen BK. Anti-inflammatory effects of exercise: role in diabetes and cardiovascular disease. Eur J Clin Invest. (2017) 47:680–11. doi: 10.1111/eci.12781

70. Malik S, Suchal K, Khan SI, Bhatia J, Kishore K, Dinda AK, et al. Apigenin ameliorates streptozotocin-induced diabetic nephropathy in rats via MAPK-NF-κB-TNF-α and TGF-β1-MAPK-fibronectin pathways. Am J Physiol Renal Physiol. (2017) 53:554–63. doi: 10.1152/ajprenal.00393.2016

71. Tajic I, Lovic D. Hypertension and cardiometabolic diseases. Front Biosci (Schol Ed). (2018) 10.16674/si5.0001099

72. Katsimardou A, Imprialos K, Stavropoulos K, Sachinidis A, Doumas M, Lascaratos J. Activation of Nrf2 by H2O2: de novo synthesis versus nuclear translocation. In: Cadenas E, Packer L editors. Methods in Enzymology. Cambridge, MA: Academic Press. (2013). pp. 157–71. doi: 10.1016/b978-0-12-405388-1.00009-4

73. Tajic I, Lovic D. Hypertension and cardiometabolic diseases. Front Biosci (Schol Ed). (2018) 10.16674/si5.0001099
inhibiting the hypoxy inducible factor 1α–KV1.5 channel pathway. *Chem Biol Interact.* (2020) 317:108942. doi: 10.1016/j.cbii.2020.108942

85. Simontin M, Casanova P, Citterio L, Messaggio E, Lanzani C, Manunta P. Endogenous ouabain and related genes in the translation from hypoxia to renal diseases. *Int J Mol Sci.* (2018) 19:1948. doi: 10.3390/ijms19071948

86. Wei X, Gao P, Pu Y, Li Q, Yang T, Zhang H, et al. Linking type 2 diabetes mellitus, cardiac hypertrophy and depression in a diurnal animal model. *Sci Rep.* (2019) 9:11865. doi: 10.1038/s41598-019-48326-7

87. Zhu ZY, Gao T, Huang Y, Xie J, Xie ML. Apigenin-induced HIF-1α inhibitory effect improves abnormal glucolipid metabolism in Ang II/hypoxia-stimulated or HIF-1α-overexpressed H9c2 cells. *Phytochemistry.* (2019) 62:152713. doi: 10.1016/j.phytomed.2018.10.010

88. Zhou ZY, Gao T, Huang Y, Xie J, Xie ML. Apigenin ameliorates hypertension-induced cardiac hypertrophy and down-regulates cardiac hypoxia inducible factor-1α in rats. *Food Funct.* (2016) 7:3992–8. doi: 10.1039/c5fo01464f

89. Huang Y, Lei L, Liu D, Jovin I, Russell R, Johnson RS, et al. Normal glucose uptake in the brain and heart requires an endothelial cell-specific HIF-1α-dependent function. *Proc Natl Acad Sci U S A.* (2012) 109:17478–83. doi: 10.1073/pnas.1209281109

90. Cerychova R, Pavlinkova G. HIF-1, metabolism, and diabetes in the embryonic and adult heart. *Front Endocrinol.* (2018) 9:460. doi: 10.3389/fendo.2018.00460

91. Krishnan J, Suter M, Windak R, Krebs T, Felley A, Montessuit C, et al. Activation of a HIF1α-PARP axis underlines the integration of glycolytic and lipid anabolic pathways in pathologic cardiac hypertrophy. *Cell Metab.* (2009) 9:512–24. doi: 10.1016/j.cmet.2009.05.005

92. Cole MA, Abd Jamil AH, Heather LC, Murray AJ, Sutton ER, Slingo M, et al. On the pivotal role of PARPαs in adaptation of the heart to hypoxia and why fat in the diet increases hypoxic injury. *FASEB J.* (2016) 30:2684–97. doi: 10.1096/fj.201500949

93. Liu J, Ni Z, Shen H, Tu Z, Liu H, Lu R, et al. The non-additive contribution of hydroxy substrasts to Akt kinase–apigenin affinity. *Mol Simulation.* (2014) 41:653–62. doi: 10.1080/08927022.2014.913099

94. Wang Y, Chen S, Yu O. Metabolic engineering of flavonoids in plants and microorganisms. *Appl Microbiol Biotechnol.* (2011) 91:949–56. doi: 10.1007/s00253-011-3449-2

95. Farzad MA, Abbaspadi Z, Ardekaní MR, Rahimi R, Farzadí F, Parsley: a review of ethnopharmacology, phytochemistry and biological activities. *J Tradit Med Clin.* (2013) 33:815–26. doi: 10.1007/s12272-014-0018-2

96. Liu G, Zhuang L, Song D, Lu C, Xu X. Isolation, purification, and antioxidant activity of flavone C-glycosides from antioxidant of bamboo leaves by macroporous resin column chromatography. *Food Funct.* (2017) 8:1307–16. doi: 10.1039/c6fo01460b

97. Lin X, Yang P, Reece EA, Yang P. Pregestational type 2 diabetes mellitus induces cardiac hypertrophy in the murine embryo through cardiac remodeling and fibrosis. *Am J Obstet Gynecol.* (2017) 217:216:e1–13. doi: 10.1016/j.ajog.2017.04.008

98. Bilo C, Einat H, Barak D, Zimmert P, Vishnevskaya-Dai V, Govrin A, et al. Linking type 2 diabetes mellitus, cardiac hypertrophy and depression in a diurnal animal model. *Sci Rep.* (2019) 9:11865. doi: 10.1038/s41598-019-48326-7

99. Wang F, Yin J, Ma Y, Jiang H, Li Y. Vitexin alleviates lipopolysaccharide-induced in vitro cell injury by inhibiting HMGB1 release. *Med Mol Rep.* (2017) 45:1079–86. doi: 10.3892/mmr.2017.7114

100. Lin X, Yang P, Reece EA, Yang P. Pregestational type 2 diabetes mellitus induces cardiac hypertrophy in the murine embryo through cardiac remodeling and fibrosis. *Am J Obstet Gynecol.* (2017) 217:216:e1–13. doi: 10.1016/j.ajog.2017.04.008

101. Liu G, Zhuang L, Song D, Lu C, Xu X. Isolation, purification, and antioxidant activity of flavone C-glycosides from antioxidant of bamboo leaves by macroporous resin column chromatography. *Food Funct.* (2017) 8:1307–16. doi: 10.1039/c6fo01460b

102. Qin W, Ren B, Wang S, Liang S, He B, Shi X, et al. Apigenin and naringenin ameliorate PKCβ-associated endothelial dysfunction via regulating ROS/caspase-3 and NO pathway in endothelial cells exposed to high glucose. *Vascul Pharmacol.* (2016) 85:39–49. doi: 10.1016/j.vph.2016.07.006
in 3T3-L1 adipocytes and attenuated lipid accumulation in obese mice. *Front Pharmacol.* (2017) 8:589. doi: 10.3389/fphar.2017.00589

122. Kwon E-B, Kang M-I, Ryu HW, Lee S, Lee J-W, Lee MK, et al. Acacetin enhances glucose uptake through insulin-independent GLUT4 translocation in L6 myotubes. *Phytotherapy.* (2020) 15:3178. doi: 10.1016/j.phymed.2020.153178

123. Wei Y, Yuan P, Zhang Q, Fu Y, Hou Y, Gao L, et al. Acacetin enhances endothelial dysfunction and aortic fibrosis in insulin-resistant SHR rats by estrogen receptors. *Mol Biol Rep.* (2020) 47:8899–918. doi: 10.1007/s11033-020-05746-3

124. Krishna MS, Joy B, Sundaresan A. Effect on oxidative stress, glucose uptake level and lipid droplet content by Apigenin 7, 4'-dimethyl ether isolated from *Piper longum L.* *J Food Sci Technol.* (2015) 52:561–70. doi: 10.1007/s13197-014-1387-6

125. Pan G, Zhao L, Xiao N, Yang K, Ma Y, Zhao X, et al. Total synthesis of 8-(6′-umbelliferyl)-apigenin and its analogs as anti-diabetic reagents. *Eur J Med Chem.* (2016) 122:674–83. doi: 10.1016/j.ejmech.2016.07.015

126. Yang M, Jiang ZH, Li CG, Zhu YJ, Li Z, Tang YZ, et al. Apigenin prevents metabolic syndrome in high-fructose diet-fed mice by Keap1-Nrf2 pathway. *Biomed Pharmacother.* (2018) 105:1283–90. doi: 10.1016/j.biopha.2018.06.108

127. Osada M, Imaoka S, Funae Y. Apigenin suppresses the expression of VEGF, an important factor for angiogenesis, in endothelial cells via degradation of HIF-1α protein. *FEBS Lett.* (2004) 575:59–63. doi: 10.1016/j.febslet.2004.08.036

128. Hollman PC, Katan MB. Health effects and bioavailability of dietary flavonols. *Free Radic Biol Med.* (1999) 31:575–80.

129. Ross JA, Kasum CM. Dietary flavonoids: bioavailability, metabolic effects, and safety. *Ann Rev Nutr.* (2002) 22:19–34. doi: 10.1146/annurev.nutr.22.111401.144957

130. Llevot A, Astruc D. Applications of vectorized gold nanoparticles to the diagnosis and therapy of cancer. *Chem Soc Rev.* (2012) 41:242–57. doi: 10.1039/c1cs15080d

131. Das S, Das J, Samadder A, Paul A, Khuda-Bukhsh AR. Strategic formulation of apigenin-loaded PLGA nanoparticles for intracellular trafficking, DNA targeting and improved therapeutic effects in skin melanoma in vitro. *Toxicol Lett.* (2013) 223:124–38. doi: 10.1016/j.toxlet.2013.09.012

132. Cheruvu HS, Yadav NK, Valicherla GR, Arya RK, Hussain Z, Sharma C, et al. LC-MS/MS method for the simultaneous quantification of luteolin, wedelolactone and apigenin in mice plasma using hanssen solubility parameters for liquid-liquid extraction: application to pharmacokinetics of Eclipta alba chloroform fraction. *J Chromatogr B Analyt Technol Biomed Life Sci.* (2018) 108:76–86. doi: 10.1016/j.jchromb.2018.01.035

133. Milanlouei S, Menichetti G, Li Y, Loscalzo J, Willett WC, Barabási AL. A systematic comprehensive longitudinal evaluation of dietary factors associated with acute myocardial infarction and fatal coronary heart disease. *Nat Commun.* (2020) 11:6074. doi: 10.1038/s41467-020-19888-2

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Xu, Li and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.